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We report the initial toxicity data with scanned proton beams at the Italian National Center for
Hadrontherapy (CNAO). In September 2011, CNAO commenced patient treatment with scanned proton
beams within two prospective Phase II protocols approved by the Italian Health Ministry. Patients with
chondrosarcoma or chordoma of the skull base or spine were eligible. By October 2012, 21 patients had
completed treatment. Immobilization was performed using rigid non-perforated thermoplastic-masks and
customized headrests or body-pillows as indicated. Non-contrast CT scans with immobilization devices in
place and MRI scans in supine position were performed for treatment-planning. For chordoma, the pre-
scribed doses were 74 cobalt grey equivalent (CGE) and 54 CGE to planning target volume 1 (PTV1) and
PTV2, respectively. For chondrosarcoma, the prescribed doses were 70 CGE and 54 CGE to PTV1 and
PTV2, respectively. Treatment was delivered five days a week in 35–37 fractions. Prior to treatment, the
patients’ positions were verified using an optical tracking system and orthogonal X-ray images. Proton
beams were delivered using fixed-horizontal portals on a robotic couch. Weekly MRI incorporating diffu-
sion-weighted-imaging was performed during the course of proton therapy. Patients were reviewed once
weekly and acute toxicities were graded with the Common Terminology Criteria for Adverse Events
(CTCAE). Median age of patients = 50 years (range, 21–74). All 21 patients completed the proton therapy
without major toxicities and without treatment interruption. Median dose delivered was 74 CGE (range,
70–74). The maximum toxicity recorded was CTCAE Grade 2 in four patients. Our preliminary data
demonstrates the clinical feasibility of scanned proton beams in Italy.
INTRODUCTION
Chordomas and chondrosarcomas are rare tumors that arise
in the base of skull and along the vertebrae [1, 2]. Although
surgical resection is the standard of care, complete resection
is seldom successful [3, 4]. Radiation therapy (RT) has
been used successfully in the adjuvant setting to reduce the
rates of local recurrence [5, 6]. However, due to the location
of these tumors near to critical organs such as the brain
stem, optic chiasm and optic nerves, it is seldom possible
to deliver the high radiation doses required to eradicate
residual tumor after surgery [7–9]. Techniques using
conventional radiation have shown local control rates of
17–50% for chordoma of the skull base. New radiation
techniques such as intensity-modulated radiotherapy
(IMRT), highly conformal RT techniques, and charged
particles have been used to circumvent this limitation of
conventional RT [10–17].
Protons and other charged particles have an inverted
dose profile that allows delivery of high doses to the target
while minimizing dose to the surrounding organs at risk
[18, 19]. As charged particles travel through tissue they
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gradually decelerate and transfer energy to tissues, resulting
in molecular excitation and ionizations. A sharp rise in
energy transfer, termed the Bragg peak, takes place near
the end of the finite range of the particle. For protons, the
radiation dose beyond the Bragg peak sharply drops to
zero, resulting in no radiation dose beyond this point (no
exit dose). This dose deposition differs dramatically from
photon irradiation, in which the peak dose is relatively
superficial in tissue followed by a gradual fall off in dose.
As a result, the exit dose through normal tissues with
photons can be substantial. The potentially lower dose to
non-target tissue is the primary appeal of charged particle
therapy. Proton RT has been shown to improve local
control rates in patients with chordoma and chondrosar-
coma [12, 20, 21].
In September 2011, the Italian Ministry of Health and
the local ethics committee approved two Phase II clinical
studies at the Italian National Centre for Oncological
Hadrontherapy (CNAO) for the use of proton therapy (PT)
for patients with skull base and sacral chordoma and chon-
drosarcoma. To date, 21 patients have been accrued to
these two clinical studies and all have completed their PT
treatment. During the course of proton treatment, all
patients were assessed for acute toxicity using standardized
criteria based on the Common Terminology Criteria for
Adverse Events (CTCAE version 3.0) by the attending
nurse practitioner [22]. We now report the acute toxicity
rates recorded for the initial 21 patients.
MATERIALS AND METHODS
PT at CNAO
Patient recruitment
Patients are referred to CNAO from all regions of Italy.
Based on the inclusion and exclusion criteria as stipulated
in the two single-center prospective Phase II study proto-
cols (CNAO 01/2011 and CNAO 02/2011), patients are
accrued prospectively into either of the studies. Inclusion
criteria include: completely or partially resected, recurrent
or non-resectable histologically proven chondrosarcoma
(World Health Organization [WHO] low grade) or chor-
doma of the skull base or sacrum, adequately staged (14–
85 years) patients with good performance status (Karnofsky
performance status ≥ 70) who are able to give consent for
the study. Exclusion criteria include: patients with poor per-
formance status (Karnofsky performance status <70) with
metastatic disease with inadequate staging or histological
diagnosis, previous radiotherapy in affected region, con-
comitant chemotherapy or high grade chondrosarcoma
(WHO Grade 3), extensive metal instrumentation, inability
to deliver prescribed dose without overdose to normal struc-
tures, or pregnancy. The primary endpoints were early local
response (within 90 days) and acute toxicity. Secondary
endpoints included: long-term local response, disease-free
survival, overall survival and long-term toxicity.
At CNAO, protons (and also carbon ions) are generated
with a ring synchrotron and transferred to three treatment
rooms with fixed horizontal and/or vertical beam lines. It is
also possible to accelerate carbon ions up to 400Mev. Of
the three treatment rooms, two are equipped with the lateral
beam line only, while one has both vertical and horizontal
beam lines. At the moment, protons of energies of 60–250
MeV are generated. Proton beams are scanned laterally and
vertically across the target volume using scanning magnets,
while variation in depth is modulated by energy changes in
the synchrotron. This active system of delivery does not
require the use of the heavy and expensive collimators and
compensators used in passive delivery systems. This active
system also reduces the amount of neutron contamination
to the patient. The maximal field size of the beam line is
20 × 20 cm. All rooms are equipped with in-room optical
tracking system (OTS) and patient verification system
(PVS) for treatment position verification. Patients are
moved into the treatment position by use of a robotic treat-
ment couch with movement with six degrees of freedom.
Immobilization is performed using customized rigid non-
perforated thermoplastic-masks, mouth-bites and head-rests
and/or moldable body-pillows. The position of the patient’s
head may be rotated laterally and/or flexed/extended to
achieve the optimal geometry of beam entry angles (for
target coverage and/or OARs avoidance). A simulation CT
scan without intravenous contrast is performed for every
patient in the supine position with immobilization devices
in place, to be used for treatment planning. The CT slice
thickness is fixed at 2 mm. The simulation CT is used for
calculating the treatment plan. Contrast medium is not used
as this would affect particle range calculation. In order to
convert Hounsfield numbers to stopping power for parti-
cles, images are acquired with a fixed exposition protocol.
Magnetic resonance imaging (MRI) is performed in order
to improve soft tissue visualization and tumor infiltration.
Whenever possible MRI is performed with the patients
immobilized in the exact set-up conditions (thermoplastic
masks, customized mouth-bites and moldable pillows).
Image fusion is performed with non-deformable algorithms
based on anatomical landmarks.
The gross tumor volume (GTV) contains the primary or
residual tumor. The volume includes all areas interpreted as
involved by macroscopic tumor. Typically for chordoma,
the GTV is defined as the area of hyperintense signal on
T2-weighted MRI and the contrast-enhancing area on
T1-weighted MRI sequences. The clinical target volume
(CTV) includes the anatomical extension of the tumor, sur-
gical field and suspected microscopic spread of disease.
The planning target volume (PTV) is defined as the CTV
plus 2 mm in the skull base and CTV plus 4 mm in the
sacrum.
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Treatment plans were generated on the Siemens SyngoPT
treatment-planning system using the inverse treatment algo-
rithm. Proton doses are expressed as cobalt grey equivalent
(CGE) using a radio biological effect of 1.1 [23]. The pre-
scribed doses are 70 CGE for chondrosarcoma and 74 CGE
for chordoma using 2 CGE daily fractions, treating five days
a week over 7–7.5 weeks. 70 CGE and 74 CGE were chosen
based on previously published data and have been shown
to be safe and effective. The intention of this study is to
replicate previously published experience using the experi-
mental in-house designed synchrotron at CNAO. Once its
safety and efficacy has been shown, a further dose escalation
study could be proposed. The median number of treatment
fields is 2 (range, 1–3). PT is usually delivered in two
phases: phase 1 to 54 CGE and then phase 2 to 70 or 74
CGE depending on tumor type. Phase 1 is usually delivered
with single beam optimization (SBO) using two fields and
phase 2 with intensity-modulated proton therapy (IMPT)
using 2–3 fields to increase the robustness of the treatment
plan. IMPT is analogous to IMRT for photons, using an
inverse planning algorithm to optimize target coverage while
maintaining dose constraints to organs at risk (OARs).
Quality assurance procedures
Daily quality assurance (QA) procedures include checks on
the patient positioning system (PVS) and image verification
system to ensure an accuracy of <±1 mm. This involves
the use of imaging phantoms with implanted ball-bearings
and cross-checks between the PVS and optical tracking
system (OTS). This is done every day before the first
patient is treated. Patient-specific quality procedures include
treatment-plan verification using a water phantom and mul-
tiple pinpoint ion chambers to assess dose distribution, par-
ticularly in regions of high-dose gradients and tissue
inhomogeneity. For the very first patient, post PT auto-
activation PET imaging (within 10 min) was performed to
assess the range of the treatment portals.
Acute toxicity
The attending physician and nurse practitioner assessed
patients once a week during the course of PT (7–7.5
weeks). The nurse practitioner recorded the maximal acute
toxicity for each patient based on standardized acute tox-
icity forms generated from National Cancer Institute
Common Terminology Criteria for Adverse Events
(CTCAE) version 3.0 [22]. The assessment criteria and
types of toxicity assessment depend on the site of treatment
(i.e. skull base or sacrum). Clinical photographs are taken
to document skin and/or mucosal toxicity if they develop.
At the patient’s first follow-up visit three months after com-
pletion of PT, re-assessment for resolution and/or persist-
ence of any acute toxicity is performed. If any unexpected
or severe toxicity should develop, PT was to be stopped
and a review of the treatment plans and/or dose-volume
histograms undertaken urgently to identify any potential
cause.
Mini mental state exam
There is a suggestion that the use of PT can reduce impair-
ment of neuropsychological and intelligence quotient devel-
opment [24]. However even with PT, patients with skull
base tumors may still receive significant radiation to the
neighboring brain tissues [25, 26]. To assess the neurocog-
nitive impact of PT on patients receiving PT to the skull
base, we used the mini mental status examination (MMSE)
[27]. The attending physician and nurse practitioner per-
formed this examination during weeks 1 and 7 of PT and at
the first follow-up appointment. This MMSE is a validated
tool for neurological function assessment in patients receiv-
ing RT to the brain. The toxicity may be subsequently corre-
lated to both dose and volume parameters in the treatment
plan. The MMSE was initially derived to screen and quan-
tify the severity of cognitive dysfunction in patients with
dementia and was first developed by Folstein in 1975 [27].
MMSE has been used to assess neurotoxicity after brain
RT. Understandably, the volume of brain receiving RT in
photon RT for primary brain tumors will be much larger
than the volume of brain irradiated in patients with skull
base PT. However as our patients are expected to have fa-
vorable prognosis after PT, it is important to document any
neurological impact after PT.
The MMSE is divided into the following sections: orien-
tation to time, orientation to place, immediate recall, atten-
tion, delayed verbal recall, naming, repetition, three-stage
commands, reading, writing and copying. The MMSE
offers a quick and simple way to quantify cognitive func-
tion and screen for cognitive loss. It tests the individual’s
orientation, attention, calculation, recall, language and
motor skills. Each section of the test involves a related
series of questions or commands. The individual receives
one point for each correct answer. To give the examination,
the individual needs to be seated in a quiet, well-lit room.
The tester asks the patient to listen carefully and answer
each question as accurately as he/she can. The score is
determined by adding the number of correct responses. The
individual can receive a maximum score of 30 points. A
score below 20 usually indicates cognitive impairment.
Follow-up during and after PT
During the course (7–7.5 weeks) of PT, patients have
repeated 3-Tesla (3T) MRI scans every 1–2 weeks. This
has been mandated by the health authorities to document
early response to treatment (or progression), and to study
early radiological changes within the tumor, as PT is still
considered experimental therapy in Italy. In addition to the
non-enhanced and fat-suppressed T1 and T2 weighted mag-
netic resonance (MR) images, diffusion weighted (DW)
images were acquired with motion-probing gradient (MPG)
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pulses applied sequentially along three directions (x, y, and
z axes) with four b-factors (0, 50, 400 and 1000 seconds/
mm2). The minimum, maximum, mean and standard devi-
ation values of apparent diffusion coefficients (ADC) were
generated after placing regions of interest manually, encom-
passing the GTV on the ADC map.
At the first follow-up appointment (three months after
completion of PT), patients have another MRI for tumor re-
sponse assessment. Patients are followed up three-monthly
for the first and second year, then six-monthly for the third
and fourth years, and thereafter annually up to 10 years.
Late toxicity is scored using the CTCAE version 3.0 as
defined by toxicity occurring after 90 days of PT [22].
These toxicity scores are to be re-categorized using the
RTOG or LENT/SOMA criteria, especially when docu-
menting late effects [28, 29]. It is crucial that patients con-
tinue to be followed up here at CNAO with clinical visits
and MRI scans and assessed by the same team of doctors
and same MRI unit.
RESULTS
Demographic data
From September 2011 to September 2012, 21 patients were
recruited into the two study protocols and completed PT.
Eleven patients (52%) have had their first post-treatment
clinical follow-up and MRI scans.
Patients were equally divided between the sexes and
their median age was 50 years (range, 21–74). There were
16 patients with chordoma and five with chondrosarcoma.
15 patients had tumors of the skull base and six had tumors
of the sacrum. The most common tumor was chordoma of
the skull base. The majority of patients had primary disease
and had undergone prior surgery. The median incidence
of surgical resection was one, but some patients had been
treated with up to four resections in recurrent cases
(Table 1). Major symptoms at presentation included visual
disturbance/diplopia, pain/paresthesia, and mass/swelling.
The median dose delivered was 74 CGE (range, 70–74)
and the median treatment time was 50 days (range, 44–58)
(Table 2). A typical treatment plan and dose distribution is
shown in Fig. 1.
Acute toxicity
The mean follow-up time was five months (range, 1–12).
The maximal grade of toxicity recorded by patients was
Grade 2 (skin and nausea). The most common types of tox-
icity were radiation dermatitis (skin) and headaches
(Table 3). With regards to the temporal pattern of acute tox-
icity, the start and/or peak of toxicity was usually recorded
in the final three weeks of PT and then resolved completely
by the first follow-up. All patients had complete resolution
of acute toxicity at the first follow-up (at three months), but
some patients had persisting symptoms from before
surgery, i.e. tumor-related rather than PT-related symptoms,
which at times was a confounding factor. The management
of these acute side-effects included special skin-care
(topical treatment), steroids, painkillers and anti-nausea
medication. We should specifically mention certain types
of expected toxicity: two patients with pharyngeal toxicity
with tumor with pharyngeal extension. We have separated
tumours of the skull base from those of the sacrum/pelvis
in our description of toxicity events.
All patients completed their PT without any delays. In
total, 19 patients had acute toxicity: four patients recorded
nine Grade 2 acute toxicity events; 18 patients recorded
104 Grade 1 events. Two patients did not experience any
acute toxicity at all during PT. Nineteen (90%) patients had
toxicity of Grade 1–2; 18 (86%) had Grade 1 toxicity; four
(19%) had Grade 2 toxicity; none (0%) had Grade 3–4 tox-
icity. The most common and/or persistent toxicity events
Table 1. Patient characteristics
n %
Total 21 100
Histology
Chordoma 16 76
Chondrosarcoma 5 24
Location
Skull base 15 71
Sacrum 6 29
Sex
Male 11 52
Female 10 48
Median age (years) 50 Range, 21–74
Extent of disease at PT
Primary 16 76
Recurrent 5 24
Previous surgery
Yes 18 86
No 3 14
Median no. of surgery 1 Range, 1–4
Presenting symptoms at diagnosis
Diplopia/visual disturbance 7 33
Pain/paresthesia 4 19
Mass/swelling 4 19
Ear symptoms 1 5
Speech symptoms 1 5
No symptoms 1 5
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recorded in patients with skull base PT were skin toxicity/
RT dermatitis and headache (Table 4 and Fig. 2). The inci-
dence increased after week 5 and peaked in the final
(seventh) week. The remainding types of toxicities were
sporadic and competely resolved within 1–2 weeks. The
most common toxicity in tumors of the sacrum/pelvis was
RT dermatitis (Table 5 and Fig. 3). All patients had com-
plete resolution of acute toxicities after PT (at first follow-
up three months after completion of PT).
MMSE
Of the patients with skull base PT, we collected data for 14
patients with MMSE at the beginning of PT and 10 patients
at the end of PT (Fig. 4). In the initial assessment (week
1): the mean score was 27, median score was 28, minimum
score was 20, maximum score was 30, and valid number of
tests was 14. At the end of PT (week 7): the mean score
was 28, median score was 29, minimum score was 24,
maximum score was 30, and valid number of tests was 10.
At the first follow-up: the mean score was 28, median score
was 28, minimum score was 28, maximum score was 28,
and valid number of tests was 2 (Table 6).
MRI during PT and DW imaging/ADC evaluation
There were no significant changes in tumor size in any of
the 21 patients, based on the Response Evaluation Criteria
In Solid Tumors criteria on serial MRI scans performed
during PT. In the preliminary analysis for the first three
patients (data not shown), the initial ADC for skull base
Table 2. Treatment and tumor characteristics
n % Range
PT Dose
74CGE/37# 16 76
70CGE/35# 5 24
Median treatment time
(days)
50 44–58
Median no. of fields 2 1–3
Mean follow-up
(months)
5 1–12
No. of patients with first
follow-up/MRI scans
10 48
Mean Median Range
GTV (mls) 126 17 0.6–1429.6
Skull base 20 18 0.6–99.1
Sacrum 389 144 10.6–1429.6
CTV1 (mls) 138 47 14–998.1
Skull base 58 37 14–221.7
Sacrum 363 144 103.6–998.1
CTV2 (mls) 208 45 6.7–2311.6
Skull base 39 22 6.7–123.5
Sacrum 573 199 50.3–2311.6
PTV1 (mls) 178 64 21.0–1134.4
Skull base 75 48 21.0–279.6
Sacrum 467 227 181.4–1134.4
PTV2 (mls) 238 51 11.1–2847.8
Skull base 48 31 11.1–150.0
Sacrum 712 283 90.3–2847.8
Fig. 1. Dose distribution of a patient with skull base chordoma.
Table 3. Incidence of toxicity events
Total events
recordeda
Number of
patients affected
%
Total 21 100
No toxicity 2 10
Toxicity any grade 113 19 90
G1 toxicity 104 18 86
Skull base 95 14 67
Sacrum 9 4 19
G2 toxicity 9 4 19
Skull base 5 2 10
Sacrum 4 2 10
G3 toxicity 0 0 0
aMay be extension of same event, i.e. from week 1 to 2
without resolution.
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Fig. 2. Cumulative toxicity scores by type of toxicity per week of proton therapy (PT) for patients with chordoma
or chondrosarcoma of the skull base.
Table 4. Cumulative score for each symptom for skull base PT patients per week
Cumulative score for each symptom for
skull base PT patients per week
1 2 3 4 5 6 7 8 first follow-up
Vomiting 0 1 2 0 0 0 0 0 0
Nausea 0 1 2 0 1 1 1 0 0
Fatigue 0 0 0 0 0 0 0 0 0
Headache 0 2 3 3 4 5 4 2 0
Hypersomnia 0 0 0 0 0 0 0 0 0
RT dermatitis 0 0 2 4 9 12 12 0 0
Soft tissue swelling 0 0 0 0 0 0 0 0 0
Oral mucositis 0 0 1 1 1 1 1 1 0
Dysphagia 0 1 1 0 0 0 0 0 0
Table 5. Cumulative score for each symptom for pelvic PT patients per week
Cumulative score for each symptom for
pelvic PT patients per week
1 2 3 4 5 6 7 8 first follow-up
Diarrhea 0 0 0 0 0 0 0 0 0
Nausea 0 0 0 0 0 0 0 0 0
Rectal pain 0 0 0 0 0 0 0 0 0
Cystitis (non-infective) 0 0 0 0 0 0 0 0 0
Superficial tissue swelling 0 0 0 0 0 0 0 0 0
Proctitis 0 0 0 0 0 0 0 0 0
Dermatitis 0 1 1 2 2 5 6 0 0
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chondrosarcoma appears to be much higher than for that of
chordoma. The median ADC over the proton treatment was
2 × 10−3 mm2/sec and 1.5 × 10−3 mm2/sec in the chondrosar-
coma and chordoma, respectively. There was no apparent
difference in the normalized ADC during proton treatment
for the three patients. However, a slight decrease at the first
follow-up (after three months) was noted for the patient with
chondorsarcoma of the skull base.
Statistical analysis
We performed the paired student t-test, which showed no
significant difference. Therefore, we concluded that there is
no statistical change of scores for the MMSE from the start
to end of PT. However, we need more patients and longer
follow-up (potentially with MMSE at the one-year follow-
up and annually) for more concrete conclusions.
DISCUSSION
Apart from increased tumor control from dose escalation,
another major promise of PT is to decrease the incidence of
acute and late treatment-related effects by reducing the
Fig. 3. Cumulative toxicity score by type of toxicity per week of proton therapy (PT) for patients with chordoma
or chondrosarcoma of the sacrum.
Fig. 4. Mini Mental State Exam (MMSE) scores at start and end of proton therapy (PT).
Table 6. MMSE scores at the start and end of PT
Start of PT End of PT
Mean MMSE score 27 28
Median MMSE score 28 29
Range 20–30 24–30
Valid scores 14 10
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amount of radiation given to normal tissues. This is espe-
cially relevant in pediatric patients, young adults or patients
with curable cancers. As technology advances with the de-
velopment of pencil-beam scanning we can further reduce
the dose to normal tissues using passive delivery systems
[30, 31]. This reduction in late effects is often cited as the
justification for investment in these expensive systems.
We have compared our data to published trials.
Unfortunately, there have been only a few papers on late
effects and even fewer papers with details on acute effects
[21, 32–36]. The published studies reported on late effects
predominantly, with few details on acute toxicity. The section
below includes a short literature review of the published data
on PT in skull base chordoma and chondrosarcoma.
Early effects of PT
Noel et al. from Orsay described the early effects during
PT and six weeks after PT [21]. All patients described
early side-effects of: asthenia, loss of appetite, transitory
temporal and/or fronto-parietal alopecia, mild erythema and
nausea. There were no early side-effects that required dis-
continuation of RT or hospitalization. A total of 42 patients
experienced one or more late complications. The median
time of onset of late complications was eight months
(range, 2–43 months). Late complications recorded were:
eight patients with visual disorders; two patients with loss
of vision; 11 patients with clinical neuropsychological dis-
orders; there were no cases of brain necrosis or leukoence-
phalopathy, but one patient had asymptomatic bilateral
temporal necrosis on imaging; 21 patients experienced
decreased hearing loss comprised of 16 with unilateral and
five with bilateral hearing loss; 17 patients had decreased
pituitary function, of which nine patients had complete pi-
tuitary hormonal replacement, and eight had partial pituit-
ary dysfunction.
Ares 2009 et al. of the Paul Scherrer Institut (PSI) only
reported on late events [34]. There were four patients with
high-grade (Grade 3–4) toxicity, and the actuarial five-year
freedom from high-grade toxicity was 94%. One patient
had Grade 3 unilateral optic neuropathy compression on
chiasm, supra-sellar extension; one patient had Grade 4
unilateral optic neuropathy that developed 12 months after
PT; two patients had Grade 3 temporal lobe parenchyma
damage, requiring high doses of steroids; five patients had
asymptomatic circumscribed white matter changes in the
temporal lobe (Grade 1 leukoencephalopathy); 7.8% of
patients had temporal lobe lesions confined to the high-
dose region of PT, which included a 2–5 mm margin
toward the temporal lobes. In four patients, MRI changes
remained stable or resolved completely. In one patient,
MRI changes continued to progress up to the time of ana-
lysis. Weber et al. at the PSI reported on late events that
were seen in four (14%) patients [33]. Four patients had pi-
tuitary insufficiencies and required hormonal replacement
therapy. No brainstem or optical pathway necrosis was
observed despite high dose to these critical structures. The
overall three-year complication-free survival rate was
82.2%. Rutz 2008 et al. reported on pediatric patients with
tumors of the skull base and spine and reported acute
Grade 1–3 skin reaction, and Grade 1 alopecia [35].
Hug 2002 et al. reported on pediatric patients where
he found acute side-effects during PT to be within the
expected range [36]. For most patients, the side-effects
consisted of temporary epilation over the treatment area,
skin erythema, occasional headaches, fatigue, and loss of
appetite. No treatment breaks were required for patients
undergoing proton RT alone. Severe late effects were
observed in two (7%) of 29 patients: one patient had
cerebellar and brainstem parenchyma damage. This
patient required two surgical resections for posterior
fossa regrowth followed with pre- and post-operative
combined photon and proton RT at 75.4 CGE. The
patient then developed right-sided weakness and ataxia.
One patient had temporal lobe damage, which was uni-
lateral and associated with upper extremity sensory
deficit. Eight patients (27%) developed intra- and para-
sellar tumors.
Late effects of PT
The possible late effects as reported in the literature
included: pituitary dysfunction, visual impairment, temporal
lobe necrosis, cochlear and hearing loss. The patients in
this study will be followed up with neurologists, ophthal-
mologists, audiometrists and endocrinologists for late treat-
ment effects.
Munzenrider 1999 et al. reviewed the late effects on the
following normal organs [20]:
Brain stem and cervical spinal cord
The probability of survival free of significant brain stem
toxicity was 92% vs 87% (five and 10 years after PT;
n = 367, dose 63–79.2 CGE, mean follow-up = 42.5
months). Three patients died from brain stem injury, and
3.9% of patients had significant cervical myelopathy
(n = 78, chordoma and chondrosarcoma, mean follow-up =
46.4 months, PT dose 64.5–79.2 CGE).
Brain
The probability of temporal lobe injury was 8% and 13% at
2 and 5 years, respectively. Neuropsychological function
was evaluated prospectively in 38 patients, for temporal
lobe doses of 69.6–75.6 CGE. Significant psychomotor
slowing of reaction time and motor speed was shown for
the group as a whole.
Vision, hearing and cranial nerve function
Optic neuropathy occurred in 12 of 274 patients (4.4%)
who received doses of 63.4–79.4 CGE; the median dose to
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the optic structures in injured patients was 62.1 CGE. The
patch technique was significantly related to development of
optic neuropathy. Patch techniques meant that passive de-
livery systems were used, as compared to the active beam
scanning system at CNAO. Significant audiographical
hearing loss occurred 2–5 years after PT in 15 of 33
patients. Two-thirds of patients who received ≥ 62.7 CGE
to the cochlea or auditory nerve progressed to hearing loss
quite rapidly after onset (which later led to reduced dose
constraints ≤ 62 CGE, at least on one functional side).
Cranial injury was observed in 15 of 27 patients; the esti-
mated probability of neuropathy rose from 1% at 62 CGE
to 5% at 73.2 CGE. The defined dose constraints for the
brainstem, optic nerves, chiasm, cochlea, and auditory
nerves were as above.
Endocrinopathy
There were 79 patients with skull base sarcoma who
received ≥ 40 CGE to the pituitary gland. The prescribed
doses were 50.8 – 79 CGE (median 71.5 CGE), and 32
patients (40%) developed endocrinopathy (15–23% had
deficiencies in luteinizing hormone, prolactin, thyroid-
stimulating hormone, and/or cortisone) and the latent
period to endocrinopathy was 8–10 years.
Carbon ion radiotherapy
Ions such as carbon ions have also been used to treat chor-
doma and chondrosarcoma with excellent results [15, 16, 37–
39]. Ions combine the physical advantages of protons with the
higher radiobiological effect of ions within the Bragg peak
due to the increased linear energy transfer (LET). Published
rates of acute and late toxicity are comparable if not less than
with protons [15, 16]. Both technologies are still developing
and it remains to be seen which will prove the superior
treatment modality. The paucity of published data makes it
difficult to compare toxicity rates of ions, protons and
photons (i.e. SRT, SRS, Gamma Knife series).
In agreement with published data, the rates of acute tox-
icity recorded in this study were negligible, even when a
high dose (74 CGE) was delivered to large tumors
(GTV > 2000 mls). None of the patients required any treat-
ment breaks attributable to acute toxicity, and treatments
were completed without significant delays. Although the
data presented here (from only 21 patients) are very prelim-
inary, this study provides some evidence that scanned PT
appears to have minimal acute effects on patients during PT.
Hopefully this can translate into low or no late effects with
extended follow-up. All our patients were treated using
active pencil-beam scanning PT and we hope to compare
their results to those of patients treated using passive systems
at other centers by matched pair analysis when data are more
mature. This paper is not intended to prove the superiority
of one system (pencil beam scanning (PBT) vs passive
systems); rather it is meant to show that the system
developed at CNAO is safe and efficacious for the treatment
of skull base and sacrum chondrosarcoma and chordoma.
It is largely accepted that PBT is on the evolutionary
path in the development of PT, as it avoids the need for
fabrication of heavy compensators and collimators, has the
ability to achieve a sharper dose fall-off, and avoids the
need for patch fields and junction shifts. However, such a
high level of precision and accuracy is more challenging
when treating moving targets or varying organ-filling or
tissue densities. New techniques are being developed to
mitigate these issues: smaller spot sizes, faster or volumet-
ric rescanning, and daily cone beam CT image guidance.
Thus the decision for passive or active systems is dependent
on the costs, existing infrastructure, man-power, and patient
population at each center.
The reported rates of late toxicity range from 5–17%
with some cases of serious Grade 4 damage [20]. This com-
pares to a rate of 0–5% ate toxicity in studies with conven-
tional, stereotactic radiotherapy and radiosurgery [10, 11,
40, 41]. However maximal RT doses delivered in these RT
studies were 60–65 Gy, with a correspondingly much lower
rate of local control (five-year local control for chordoma =
36–56% vs 54–70% for PT). Therefore, one can see the
pitfalls and difficulties in comparing RT with PT.
As PT progressed during the seven weeks, there was a
gradual increase in acute toxicity events recorded. By the
final (seventh) week of PT, only four patients remained
without toxicity. The cumulative toxicity scores were low,
with Grade 2 being the most common cumulative score.
The most common grade of toxicity scored was Grade 1,
with only four patients with Grade 2 toxicity developing
in the final weeks of PT. By the first follow-up appoint-
ment three months after PT, all patients had complete
resolution of their toxicity symptoms. Figure 5 shows the
distribution of maximal grades of toxicity recorded for all
patients. About half the patients developed Grade 1 tox-
icity within the first weeks of PT, while the rest developed
Grade 1 toxicity only after week 4. Four patients devel-
oped Grade 2 toxicity after week 5, while one had Grade 2
toxicity symptoms with rapid complete resolution in week
2. At first follow-up, all patients had complete resolution
of toxicity. Basically there was no significant change in
the MMSE scores before and after PT, but we should con-
tinue assessing MMSE at first follow-up and one-year
intervals to identify any late neurocognitive effect in these
patients.
It would be unrealistic to expect that PT will have no
acute effects, especially given that some patients have large
treatment volumes and previous surgical resections (or even
multiple resections). Therefore it may not be easy to separ-
ate the effects from surgery from those due to PT (i.e. ex-
acerbation of surgical symptoms during PT such as nausea
or headaches). However, our data shows that acute toxicity
during PT is generally mild and lower than expected, given
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the same reasons mentioned previously (high doses used, big
treatment volumes, multiple surgeries). The effect of physical
dose distribution, active scanning or dose constraints applied
at CNAO will need further investigation, as do patient
factors: some patients may have some symptoms but not
find them bothersome.
As has been previously mentioned, there is a perceived
lack of good evidence to justify the routine use of PT in
cancer treatment [42–46]. It has been suggested that well-
designed Phase II trials should provide the minimal level of
evidence needed to convince the funders, governments and
public of the justification of continued research in this field
to improve the technology and reduce the costs of equip-
ment. We wish to emphasize the importance of standar-
dized toxicity assessment to minimize introduction of bias
into any comparison between new and old technology.
Furthermore, patient-based scoring systems should be
incorporated, along with physician-based assessment, and
quality of life (QoL) instruments should be used. In add-
ition to physician-directed objective assessment, subjective
patient-centered assessment instruments assessing patients’
QoL may also be important. At CNAO, we have embarked
on collecting QoL data during and after PT, and attempts
will be made to correlate toxicity to QoL.
CONCLUSION
This Phase II study has demonstrated the safety of PT for
patients with chordoma or chondrosarcoma of the skull
base who received scanned beam PT at our center (CNAO).
The acute side-effects recorded were predominantly Grade
1–2 and were completely resolved after PT. There were no
Grade 3–4 toxicities recorded. We will continue to enroll
additional patients and follow up existing patients within
the two clinical studies to investigate the relationship
between acute and late toxicity. We have a total of 10
clinical protocols approved in CNAO; seven are for PT and
three for carbon ions. Four protocols (utilizing protons) are
actively recruiting patients. Within 2–3 years, we hope to
have more data on local control, acute and late effects. To
gather the evidence needed to convince the community of
the safety of PT, multicenter trials or pooled data from
several centers may be required for these rare tumors.
Objective standardized toxicity assessment and treatment
with standard protocols is crucial for meaningful analysis
of such pooled data. Some of these initiatives are being
explored with multi-center/institutional projects within
Europe such as Union of the Light Ion Centers of Europe
(ULICE), the European training network in digital medical
imaging for radiotherapy (ENTERVISION) and the Particle
Training Network for European Radiotherapy (PARTNER).
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